Myriad Genetics
myriad.com ↗In their words
“Also in 2025, our healthcare provider Net Promoter Score was 72.5, a level typically regarded as excellent, reflecting our continued focus on and investment in the patient and provider experience.”
“The score is calculated by subtracting the percentage of detractors (ratings of 0–6) from the percentage of promoters (ratings of 9–10), resulting in a range from -100 to 100. Since the implementation of this program in 2022, we have consistently maintained a strong NPS above 70, which we believe indicates a high level of user satisfaction and advocacy.”
Disclosed NPS over time
Every Net Promoter Score Myriad Genetics has published, by date.
NPS disclosures (2)
Also in 2025, our healthcare provider Net Promoter Score was 72.5, a level typically regarded as excellent, reflecting our continued focus on and investment in the patient and provider experience.
The score is calculated by subtracting the percentage of detractors (ratings of 0–6) from the percentage of promoters (ratings of 9–10), resulting in a range from -100 to 100. Since the implementation of this program in 2022, we have consistently maintained a strong NPS above 70, which we believe indicates a high level of user satisfaction and advocacy.
Retention disclosures (0)
No retention figures yet.
18 earlier entries are in the full version. Get full access →
Lighthouse companies in Pharma, medtech & health distribution
About these figures
Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.
NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.